Brazil, one of the major emerging powers of the world, is marking its presence in almost every dimension of the world economy, including the generic drugs industry. Identifying the importance of the country in this significant domain, we have come up with research report "2007-2011 Generic Drugs Market in Brazil" to provide an updated and detailed account of the Brazilian generic drugs industry. It examines the chief reasons why all major generic players are heading to Brazil to manufacture and sell their drugs.
Brazil is currently the largest market for generic drugs in Latin America and with the current scenario and positive future projections, it is likely to emerge amongst the most potential markets for generic drugs in the world.
The generic drugs market in Brazil witnessed an explosive growth of 38.8% and was valued in excess of US$ 1 Billion in 2006. The market was driven by several factors such as a supporting political environment, lower cost and patent expirations of several blockbuster drugs. The market is presently being dominated by domestic generic manufacturers; however, the presence of foreign firms in the market is increasing rapidly.
The growth of the market is expected to remain strong with generics expected to occupy 22.8% of the total market by 2011, enabling Brazil to become one of the largest generic markets in the world. However, despite the strong growth, several challenges still remain to be tackled, including the prevalence of cheaper non-bioequivalent "similar drugs", low prescriptions from the private sector, and low penetration levels in the private sector.
Key Findings
- Generics in Brazil occupy nearly 9.5% of the overall pharmaceutical market in terms of sales value.
- The domestic generic firms of Brazil are over-dependent on the domestic market and have less participation in foreign markets.
- The Brazilian government has made it a norm to prescribe generics in the public sector.
- Strengthening of the Brazilian Real has increased the margins of domestic players who import raw materials to manufacture generic drugs. Currently, the domestic industry mainly focuses on finishing generic pharmaceuticals.
- One of the biggest opportunities in the generic sector lies in the Antiretroviral segment.
- Non-bioequivalent "similar drugs", which are considerably cheaper than generics, are prevalent in the pharmaceutical market.
- Cardiovascular diseases are the biggest death cause in Brazil.
- Medley and EMS Sigma are the biggest generic manufacturers in Brazil.
Key Issues & Facts Analyzed
- Evaluation of past, current and future market trends.
- Discussion about the size and growth of the market.
- Analysis of healthcare indicators.
- Future prospects of the generics market.
- Analysis of various challenges and opportunities before the industry.
- Profile discussion of key players in this sector.
Key Players Analyzed
This section provides the overview, key facts, and financial information of prominent players in the Brazil Generics Market, such as Medley, EMS Sigma Pharma, Eurofarma Laboratorios Ltd., Ache Pharmaceutical Laboratories S/A and Ranbaxy.
Research Methodology Used
Information Sources: The information has been sourced from books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and over 3000 paid databases.
Analysis Method: The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.
Table of Contents
Section 1 Analyst View
Section 2 Global Generic Drugs Market
2.1 Market Size & Growth
2.2 Geographical Performance
Section 3 Brazil Demographics & Healthcare Profile
3.1 Demographics & Macroeconomic Indicators
3.1.1 Macroeconomic Indicators
3.1.2 Population
3.1.3 Life Expectancy
3.1.4 Infant Mortality Rate
3.1.5 Age Breakup
3.2 Healthcare Indicators
3.2.1 Healthcare Structure
3.2.2 Doctors & Hospital Beds
3.2.3 Healthcare Expenditure
3.2.4 Main Causes of Death
Section 4 Brazil Pharmaceutical Market
4.1 Industry Performance
4.1.1 Drug Categories
4.1.2 Market Size & Growth
4.1.2.1 Sales Value
4.1.2.2 Sales Volume
4.1.3 Private & Public Market
4.1.4 Import & Export
4.1.5 Major Pharmaceutical Segments
4.1.6 Investments
4.1.7 Performance of Key Players
Section 5 Brazil Generic Drugs Market
5.1 Market Drivers
5.1.1 Low Cost
5.1.2 Strong Investment
5.1.3 Strong Government Support
5.1.4 Patent Expiries
5.1.5 Ageing Population
5.1.6 Strengthening of Real
5.1.7 Increasing Prescription Rates
5.2 Industry Performance
5.2.1 Market Size & Growth
5.2.1.1 Sales Value
5.2.1.2 Sales Volume
5.2.2 Regulatory Environment
5.2.3 Investments
5.2.4 Performance of Key Players
5.3 Restraints
5.3.1 Dependence on Imported Raw Materials
5.3.2 Over-reliance of Domestic Generic Firms on Domestic Market
5.3.3 Lack of Awareness & Low Prescriptions in Private Sector
5.3.4 Prevalence of "Similar Drugs"
5.3.5 Counterfeit Drugs
5.4 Promising Segments in the Generic Business
5.4.1 Antiretroviral
5.4.2 Oral Contraceptives
5.4.3 Erectile Dysfunction
5.4.4 Anti-Thrombotics
5.4.5 Cardiovascular Drugs
5.4.6 Anti-diabetics
Section 6 Future Outlook (2007-2011)
6.1 Pharmaceutical Market
6.2 Generic Drugs Market
Section 7 Profiles of Key Players
7.1 EMS Sigma Pharma
7.2 Medley
7.3 Eurofarma Laboratorios Ltda
7.4 Ache Pharmaceutical Laboratories S/A
7.5 Ranbaxy
Figures
Figure 2-1: Global - Pharmaceutical Market (in Billion US$), 1999-2006
Figure 2-2: Global - Generic Drugs Market (in Billion US$), 2001-2006
Figure 2-3: Global - Revenues of Top 3 Generic Companies (in Billion US$), 2006
Figure 2-4: Global - Forecast for Generic Drugs Market (in Billion US$), 2007-2011
Figure 2-5: Global - Share of Generic Drugs in Pharmaceutical Market (%), 2006 & 2011F
Figure 2-6: Global - Generic Drugs Market by Region (%), 2006
Figure 2-7: Brazil & Global - Growth Rate of the Generic Drugs Market (%), 2006
Figure 3-1: Brazil - Nominal GDP (in Trillion BRL) 2001-2006
Figure 3-2: Brazil - Consumer Price Index (%), 2001-2006
Figure 3-3: Brazil - Currency Exchange Rates (From US$ to BRL), 2001-2006
Figure 3-4: Brazil - Foreign Direct Investment (in Billion US$), 2004-2006
Figure 3-5: Brazil - Population (in Million), 2001-2006E
Figure 3-6: Brazil - Life Expectancy of Male & Female (in Years), 2001-2006E
Figure 3-7: Brazil - Infant Mortality Rate (per '000 Live Births), 2001-2006E
Figure 3-8: Brazil - Population Breakup by Age (%), 2001-2006E
Figure 3-9: Brazil - Number of Doctors (per '000 Population), 2001-2006E
Figure 3-10: Brazil - Number of Hospital Beds (per '000 Population), 2002 & 2003E
Figure 3-11: Brazil - Share of Healthcare Expenditure in GDP (%), 2001-2006E
Figure 3-12: Brazil - Per Capita Healthcare Expenditure (in US$), 2001-2006E
Figure 3-13: Brazil - Main Causes of Death (%), 2005E
Figure 3-14: Brazil - Main Causes of Death (%), 2030F
Figure 4-1: Brazil - Pharmaceutical Market Sales Value (in Billion BRL), 2001, 2002E & 2004-2006
Figure 4-2: Brazil - Pharmaceutical Market Sales Value (in Billion US$), 2001, 2002E & 2004-2006
Figure 4-3: Brazil - Pharmaceutical Market Sales Volume (in Billion Units), 2004-2006
Figure 4-4: Brazil - Share of Public & Private Pharmaceutical Market (%), 2006
Figure 4-5: Brazil - Private Pharmaceutical Market (in Billion BRL), 2004-2006
Figure 4-6: Brazil - Public Pharmaceutical Market (in Billion BRL), 2004-2006
Figure 4-7: Brazil - Pharmaceutical Exports Sales Value (in Million US$), 2004-2007F
Figure 4-8: Brazil - Pharmaceutical Exports Sales Volume (in Tons) 2004-2007F
Figure 4-9: Brazil - Pharmaceutical Imports Sales Value (in Billion US$), 2004-2007F
Figure 4-10: Brazil - Pharmaceutical Imports Sales Volume (in Tons), 2004-2007F
Figure 4-11: Brazil - Pharmaceutical Trade Deficit (in Million US$), 2004-2007F
Figure 4-12: Brazil - Share of Major Segments of Pharmaceutical Market (%), 2006*
Figure 4-13: Brazil - Pharmaceutical Investments (in Billion BRL), 2006 & 2007E
Figure 4-14: Brazil - Share of Investment in Various Pharmaceutical Segments (%), 2007E
Figure 5-1: Brazil - Price Comparison of Medley's Generic Version of Plenty with its Branded Version (in BRL), 2006
Figure 5-2: Brazil - Population above 65 Years (%), 2001-2006E
Figure 5-3: Brazil - Share of Prescriptions for Branded & Generic Drugs in Pharmaceutical Market (%), 2005 & 2006
Figure 5-4: Brazil - Share of Prescriptions for Atenolol, Cephalexin & Omeprazol in Branded & Generic Drugs Prescriptions (%), April 2006
Figure 5-5: Brazil - Share (Sales Value) of Generic Drugs in Pharmaceutical Market (%), 2006
Figure 5-6: Brazil - Generic Drugs Sales Value (in Million US$), 2004-2006
Figure 5-7: Brazil - Growth Rate of Generic Drugs Sales Value (%), 2005 & 2006
Figure 5-8: Brazil - Generic Drugs Sales Value (in Million US$), H1 2006 & H1 2007
Figure 5-9: Brazil - Share (Sales Volume) of Generic Drugs in Pharmaceutical Market (%), 2006
Figure 5-10: Brazil - Generic Drug Sales Volume (in Million Units), 2004-2006
Figure 5-11: Brazil - Generic Drugs Sales Volume (in Million Units), H1 2006 & H1 2007
Figure 5-12: Brazil - Investment in Generic Drugs (in Million US$), 2000-2006 & 2007-2011F
Figure 5-13: Brazil - Breakup of Investment in Generic Drugs Market (%), 2007-2011
Figure 5-14: Brazil - Number of Companies Manufacturing Generic Drugs, 2000 & 2006
Figure 5-15: Brazil - Share of Top Players in Generic Drugs Market (%), 2006
Figure 5-16: Brazil - Share of Imported & Locally Produced Raw Materials (%), 2006
Figure 5-17: Brazil - Number of HIV Patients* & HIV Patients on Anti-Retroviral Therapy (in '000), 2006
Figure 5-18: Brazil - Share of Top Players in Oral Contraceptives Market (%), 2006
Figure 5-19: Brazil - Share of Top Players in Erectile Dysfunction Market (%), Nov 2006
Figure 5-20: Brazil - Deaths from Cardiovascular Diseases (%), 2005 & 2030F
Figure 5-21: Brazil - Cardiovasular Drugs Market (in Million US$), 2005 & 2006
Figure 5-22: Brazil - Insulin Market (in Million US$), 2000, 2006 & 2010F
Figure 6-1: Brazil - Forecast for Pharmaceutical Market (in Billion US$), 2007-2011
Figure 6-2: Brazil - Forecast for Generic Drugs Market (in Billion US$), 2007-2011
Figure 6-3: Brazil - Contribution of Generic & Non-Generics in Growth of Pharmaceutical Market (%), 2006-2011
Figure 6-4: Brazil - Forecast for Share of Generic Drugs in Pharmaceutical Market (%), 2007-2011
Tables
Table 4-1: Brazil - Performance of Top 10 Players in Pharmaceutical Market, 2006
Table 5-1: Brazil - Patent Expiry & Sales of Key Drugs
Table 5-2: Brazil - Performance of Top Players in Generic Drugs Market, 2005 & 2006
Table 5-3: Brazil - Erectile Dysfunction Market (in Million BRL), 2005 & 2006
Table 5-4: Brazil - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 5-5: Brazil - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
